These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 28579852)

  • 1. Treatment of Myelofibrosis: Old and New Strategies.
    Iurlo A; Cattaneo D
    Clin Med Insights Blood Disord; 2017; 10():1179545X17695233. PubMed ID: 28579852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. State-of-the-Art Review on Myelofibrosis Therapies.
    Wang F; Qiu T; Wang H; Yang Q
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
    Mughal TI; Vaddi K; Sarlis NJ; Verstovsek S
    Int J Gen Med; 2014; 7():89-101. PubMed ID: 24501543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib: a new treatment option for myelofibrosis.
    Ganetsky A
    Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelofibrosis: diagnosis and treatment.
    Barranco-Lampón G; Martínez-Castro R; Arana-Luna L; Álvarez-Vera JL; Rojas-Castillejos F; Peñaloza-Ramírez R; Carballo-Zarate AA; Olarte-Carrillo I; Minamy JI; López-Salazar J; Navarrete JJ; Espinosa-Partida A; Ventura-Enríquez Y; Ruiz-Contreras JI; Aguirre-Reyes OG; Anaya-Cuéllar I; Aguilar-Luévano J; Díaz-Ramírez HF; Herrera-Olivares W; Aguilar-Hidalgo JA; Alcívar-Cedeño LM; Hernández-Caballero Á; Galaz-Cordero LE; Peña-Celaya JA; Báez-Islas PE; Bates-Martín RA; Cano-León AML; Espitia-Ríos ME; Barbosa D; Morales-Adrián J; Pacheco MJ; Delgado-López N; Neme-Yunes Y; Moralws-Hernández AE; Mújica-Martínez A; Pérez-Lizardi AB; Pérez-Gómez KD; Barragán-Ibáñez G; Martínez A; Flores-Ordúñez K; Ramírez-Hoyos P; Rosales-López MLÁ; Acosta-Maldonado BL; Jiménez-Ochoa MA; Garzón-Velásquez KB; Hernández-Ruiz E; McNally-Guillén BM; Saucedo-Montes EE; Aguilar-Andrade C; Vivas-Arteaga CL; Guerra-Alarcón LV; Milán-Salvatierra AI; Campa-Monroy DI; Cota-Rangel X; Estrada-Domínguez P; García-Camacho AS; García-Castillo C; Banda-García LI; Rodríguez-Sánchez V; Meillón-García LA; Urbina-Escalante E; Martínez-Ramírez MA; Loera-Fragoso SJ; Martínez-Coronel J; Zapata-Canto N; Gómez-Cortés SC; Medina-Coral JE; Mójica-Balderas L; Pérez-Zúñiga JM; Pérez FJ; López-Arroyo JL; Zazueta-Pozos JF; Romero-Martínez E; Romero-Rodelo H; Tapia-Enríquez AL; Soriano-Mercedes EJ; Salazar-Ramírez Ó; Vilchis-González SP; Tepepa-Flores F; Alvarado-Ibarra M
    Gac Med Mex; 2022; 158(Supl 1):26-37. PubMed ID: 37734057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
    Tefferi A; Pardanani A; Gangat N
    Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myelofibrosis: A review].
    Genthon A; Killian M; Mertz P; Cathebras P; Gimenez De Mestral S; Guyotat D; Chalayer E
    Rev Med Interne; 2021 Feb; 42(2):101-109. PubMed ID: 33243417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutics and targets in myelofibrosis.
    Waksal JA; Harrison CN; Mascarenhas JO
    Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.
    Mascarenhas J; Hoffman R
    Clin Cancer Res; 2012 Jun; 18(11):3008-14. PubMed ID: 22474318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new landscape of therapy for myelofibrosis.
    Gowin K; Emanuel R; Geyer H; Mesa RA
    Curr Hematol Malig Rep; 2013 Dec; 8(4):325-32. PubMed ID: 24101258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I treat myelofibrosis.
    Cervantes F
    Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary myelofibrosis--pathogenesis, diagnosis and treatment].
    Ghanima W; Knutsen H; Delabie J; Bruserud Ø
    Tidsskr Nor Laegeforen; 2013 Oct; 133(18):1946-50. PubMed ID: 24084971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.